These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 18647852)
21. The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. Dechanet J; Merville P; Durand I; Banchereau J; Miossec P J Clin Invest; 1995 Feb; 95(2):456-63. PubMed ID: 7532184 [TBL] [Abstract][Full Text] [Related]
22. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Popa C; Leandro MJ; Cambridge G; Edwards JC Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244 [TBL] [Abstract][Full Text] [Related]
23. Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. Malone DG; Wahl SM; Tsokos M; Cattell H; Decker JL; Wilder RL J Clin Invest; 1984 Oct; 74(4):1173-85. PubMed ID: 6384266 [TBL] [Abstract][Full Text] [Related]
24. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Thurlings RM; Wijbrandts CA; Mebius RE; Cantaert T; Dinant HJ; van der Pouw-Kraan TC; Verweij CL; Baeten D; Tak PP Arthritis Rheum; 2008 Jun; 58(6):1582-9. PubMed ID: 18512774 [TBL] [Abstract][Full Text] [Related]
25. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914 [TBL] [Abstract][Full Text] [Related]
26. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Wijbrandts CA; Remans PH; Klarenbeek PL; Wouters D; van den Bergh Weerman MA; Smeets TJ; Vervoordeldonk MJ; Baeten D; Tak PP Arthritis Rheum; 2008 Nov; 58(11):3330-9. PubMed ID: 18975323 [TBL] [Abstract][Full Text] [Related]
27. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105 [TBL] [Abstract][Full Text] [Related]
28. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642 [TBL] [Abstract][Full Text] [Related]
29. B cells in rheumatoid arthritis: from hypothesis to the clinic. Keystone EC Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525 [TBL] [Abstract][Full Text] [Related]
31. Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis. Parietti V; Chifflot H; Sibilia J; Muller S; Monneaux F Clin Immunol; 2010 Mar; 134(3):331-9. PubMed ID: 20022305 [TBL] [Abstract][Full Text] [Related]
32. Long term treatment of rheumatoid arthritis with rituximab. Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205 [TBL] [Abstract][Full Text] [Related]
33. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Palanichamy A; Roll P; Theiss R; Dörner T; Tony HP Arthritis Rheum; 2008 Dec; 58(12):3665-74. PubMed ID: 19035487 [TBL] [Abstract][Full Text] [Related]
34. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692 [TBL] [Abstract][Full Text] [Related]
35. Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Reparon-Schuijt CC; van Esch WJ; van Kooten C; Ezendam NP; Levarht EW; Breedveld FC; Verweij CL Arthritis Rheum; 2001 Sep; 44(9):2029-37. PubMed ID: 11592364 [TBL] [Abstract][Full Text] [Related]
36. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217 [TBL] [Abstract][Full Text] [Related]
37. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346 [TBL] [Abstract][Full Text] [Related]